PTG wins exclusive PolarisQB mandate across Greater China and ASEAN

PolarisQB Technologies Group and Polaris Quantum Biotech announced an exclusive representation agreement on June 18, 2026, giving PTG coverage across Greater China and Southeast Asia. The deal is meant to expand commercial partnerships for PolarisQB’s quantum-powered drug discovery platform in one of the world’s fastest-growing biopharma markets. Why it matters: - The agreement gives PolarisQB a dedicated regional channel into Greater China and the 10-member ASEAN market. - The deal could speed access to pharmaceutical companies, research organizations and CROs across a large biopharma corridor. - The arrangement is designed to support long-term collaboration around PolarisQB’s QuADD platform and regional business development. What happened: - POLARISQB TECHNOLOGIES GROUP PTE. LTD. (PTG) and Polaris Quantum Biotech, Inc. announced an exclusive Representation Agreement on June 18, 2026. - PTG will act as PolarisQB’s exclusive representative in Mainland China, Hong Kong SAR, Macau SAR, Taiwan and ASEAN. - Ms. Xu, PTG’s director of business development, said she has supported PolarisQB since its early days and sees the company as a pioneer in quantum-powered drug discovery. The details: - PTG will identify, develop and facilitate commercial opportunities across the territory. - PTG will engage pharmaceutical companies, R&D organizations and contract research organizations. - PTG will anchor PolarisQB’s regional business development and commercial engagement, drawing on its cross-border commercialization and market entry experience. - PolarisQB’s QuADD platform uses quantum annealing and quantum-inspired algorithms to search chemical spaces on the order of 10^30 candidate molecules. - QuADD is designed to optimize binding affinity, drug-likeness and synthetic feasibility in hours instead of months. - PolarisQB says QuADD outperforms generative AI methods in the quality of initial leads and the speed of molecular design. - PolarisQB says the platform offers a superior alternative to standard artificial intelligence. - PolarisQB is based in North Carolina. - PolarisQB describes QuADD as the first end-to-end drug discovery engine built directly around quantum computing for lead identification and optimization. - PTG is headquartered in Singapore. - PTG says it also advances its own independent pipeline of drug candidates. - More information is available on PolarisQB’s website and through PolarisQB’s media contact address . Between the lines: - The agreement links a U.S.-based quantum drug discovery company with a Singapore-based regional operator that can navigate local markets. - The focus on Greater China and ASEAN suggests PolarisQB wants access to a fast-growing biopharma customer base beyond the U.S. - The competitive framing around quantum computing versus generative AI signals a broader race to define the next standard in early-stage drug discovery. What’s next: - PTG is expected to begin building commercial relationships and opening partnership discussions across the covered markets. - PolarisQB and PTG now have a formal structure for expanding regional business development and strategic collaboration. - The companies are likely to use the agreement to position QuADD for biopharma engagements in Asia.